Chest Medicine
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
4 Feb, 2021 | 01:39h | UTCInvited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet
Study shows the viral load of index cases is a leading driver of SARS-CoV-2 transmission
4 Feb, 2021 | 01:35h | UTCCommentary: Understanding the drivers of transmission of SARS-CoV-2 – The Lancet Infectious Diseases
[Preprint] Meta-analysis: More than 50 Long-term effects of COVID-19
4 Feb, 2021 | 01:26h | UTCMore than 50 Long-term effects of COVID-19: a systematic review and meta-analysis – medRxiv
Commentary: 80% of COVID-19 Patients May Have Lingering Symptoms, Signs — More than 50 effects persisted after acute infection, meta-analysis shows – MedPage Today (free registration required)
Systematic review: No evidence that patients with asthma are at increased risk of COVID-19 diagnosis, hospitalization or death
4 Feb, 2021 | 01:24h | UTC
Russia’s Sputnik V COVID-19 vaccine candidate appears safe and is 91.6% effective
3 Feb, 2021 | 01:49h | UTCCommentaries: Sputnik V COVID-19 vaccine candidate appears safe and effective – The Lancet AND Russia’s “Sputnik V” COVID Vaccine Makes Strong 91.6 % Efficacy Showing In Peer-Reviewed Trial Results – Health Policy Watch AND Russia’s COVID vaccine 92% effective, even in those over 60 – CIDRAP AND Russia’s Sputnik V vaccine has 92% efficacy in trial – BBC AND Expert reaction to study looking at preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine (Sputnik) trial – Science Media Centre
Commentary on Twitter
NEW—Interim analysis of Russian #COVID19 #vaccine phase 3 trial involving nearly 20,000 participants suggests a two-dose regimen has an efficacy of 91.6% against symptomatic #COVID19. No serious adverse events were deemed to be associated with vaccination. https://t.co/40sM7f2nbS pic.twitter.com/Hzrs34uCWr
— The Lancet (@TheLancet) February 2, 2021
Covid-19: People who have had infection might only need one dose of mRNA vaccine
3 Feb, 2021 | 01:44h | UTCCovid-19: People who have had infection might only need one dose of mRNA vaccine – The BMJ
Original preprint studies: Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine – medRxiv AND Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2 – medRxiv
Ambulatory management of pulmonary embolism: A comparison of two risk-stratification scores
2 Feb, 2021 | 01:11h | UTC
Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma
2 Feb, 2021 | 01:06h | UTCSafety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Post severe COVID-19, CT reveals potentially lifetime lung damage in one-thirds of patients
2 Feb, 2021 | 01:19h | UTCOriginal Study: Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia – Radiology
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial
New Updates to the Surviving Sepsis Campaign COVID-19 Guidelines
1 Feb, 2021 | 01:56h | UTCAdditional resources: COVID-19 Guidelines – Surviving Sepsis Campaign
Commentary on Twitter
New updates to the #SurvivingSepsis Campaign #COVID19 Guidelines! Includes new recommendations for therapeutics and defines severe vs critical COVID-19.
View the full update in @CritCareMed, more infographics, and recommendations table here: https://t.co/OUuOwGJCR4#SCCMSoMe pic.twitter.com/1RGckdvoIm
— SCCM (@SCCM) January 30, 2021
[Press release – not published yet] Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 trial
1 Feb, 2021 | 01:55h | UTCCommentaries: J&J’s one-shot COVID vaccine offers hope for faster protection – Nature AND Johnson & Johnson Executive Says Vaccine Works Where It Counts: Preventing Deaths – NPR AND Novavax’s COVID Vaccine Shows High Efficacy In Trials; J&J One-Dose Shot Less So – As Europe Feuds With AstraZeneca – Health Policy Watch AND Covid vaccine: Single-dose Johnson & Johnson jab is 66% effective – BBC AND Johnson & Johnson’s COVID-19 Vaccine Results Are Better Than They May Sound – TIME AND Expert reaction to Johnson & Johnson announcing that the single-shot Janssen COVID-19 vaccine candidate met primary endpoints in the interim analysis of its phase 3 ENSEMBLE Trial – Science Media Centre AND Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released – NIH News Releases AND J&J one-dose Covid vaccine is 66% effective, a weapon but not a knockout punch – STAT
WHO announces updated definitions of extensively drug-resistant tuberculosis
29 Jan, 2021 | 01:38h | UTC
New coronavirus variants call for intensified surveillance, control, and vaccination efforts
29 Jan, 2021 | 01:56h | UTCNew coronavirus variants call for intensified surveillance, control, and vaccination efforts – STAT
How Covid-19 mutations are changing the pandemic
29 Jan, 2021 | 01:55h | UTCHow Covid-19 mutations are changing the pandemic – BBC
German officials say AstraZeneca vaccine shouldn’t be given to over-65s, citing lack of data
29 Jan, 2021 | 01:52h | UTCGerman officials say AstraZeneca vaccine shouldn’t be given to over-65s, citing lack of data – CNN
Covid-19: Cough, fatigue, sore throat ‘more common’ in new variant
28 Jan, 2021 | 01:41h | UTCCovid-19: Cough, fatigue, sore throat ‘more common’ in new variant – BBC
[Preprint] Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19
28 Jan, 2021 | 01:49h | UTCEfficacy of Colchicine in Non-Hospitalized Patients with COVID-19 – medRxiv
Commentary on Twitter
The large colchicine RCT for covid is preprint published.
It shows some consistent directional benefit for major outcomeshttps://t.co/gxtyKnMqZ5
Since this is a pill, it's safe, cheap & an early intervention (as tested here, before hospital) these findings are very encouraging pic.twitter.com/uzTSkjftFp— Eric Topol (@EricTopol) January 27, 2021
Duration of culturable SARS-CoV-2 in hospitalized patients with Covid-19
28 Jan, 2021 | 01:47h | UTC
Editorial: Covid-19 controversies: the Tocilizumab chapter
28 Jan, 2021 | 01:46h | UTCCovid-19 controversies: the tocilizumab chapter – The BMJ
Related: Contradicting earlier trials, Tocilizumab did not improve outcomes, with signs of harm, in patients with severe Covid-19 (studies and commentaries)
4 reasons we’re seeing these worrying coronavirus variants now – Covid-19 is evolving. Why now?
28 Jan, 2021 | 01:33h | UTC4 reasons we’re seeing these worrying coronavirus variants now – Vox
Long Covid: Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge
28 Jan, 2021 | 01:31h | UTCCommentary: Lung, mobility problems plague COVID-19 patients months after recovery – UPI
Opinion: Monoclonal antibodies yet to show important clinical benefit in patients with Covid-19
27 Jan, 2021 | 01:23h | UTCSee also: PulmCrit Wee – Follow-up Bamlanivimab study unmasks statistical chicanery
[Press release – not published yet] Neutralizing antibodies bamlanivimab and etesevimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
27 Jan, 2021 | 01:22h | UTCCommentary: Lilly antibody combo therapy cuts risk of COVID-19 deaths – Reuters
Commentary on Twitter
1st Phase 3 trial results on #SARSCoV2 monoclonal antibody combination with very positive results
1035 patients: 11 (2%) v (7%) for death or hospitalization and 0 vs 10 deaths in high-risk patients, given early https://t.co/BXnwCd64O9 (press release).
Coincides w/ EUA criteria. pic.twitter.com/3MjE0XtEqF— Eric Topol (@EricTopol) January 26, 2021
WHO Updated Guideline: COVID-19 clinical management
27 Jan, 2021 | 01:26h | UTCCOVID-19 Clinical management: living guidance – World Health Organization
News release: WHO recommends follow-up care, low-dose anticoagulants for COVID-19 patients
Commentary: WHO issues new clinical advice on treating COVID-19 patients – Reuters